Category Archives: Eczema

The eczema therapeutics market will witness a neutral impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavio's pandemic-focused market research, market growth is likely to increase in 2021 as compared to 2020.

Key Considerations for Market Forecast:

Major Five Eczema Therapeutics Market Participants:

AbbVie Inc.:The company offers eczema therapeutics under the brand name RINVOQ.

Alliance Pharma Plc:The company offers eczema therapeutics under the brand name Hydromol.

Bausch Health Companies Inc.:The company offers eczema therapeutics under the brand name DUOBRII Lotion.

Bayer AG:The company offers eczema therapeutics under the brand names Bepanthen and Canesten.

Eli Lilly and Co.:The company offers eczema therapeutics under the brand name OLUMIANT.

Eczema Therapeutics Market 2021-2025: Segmentation

Eczema therapeutics market is segmented as below:

The eczema therapeutics market is driven by the high prevalence of atopic dermatitis, strong pipeline landscape, and increasing product launches. In addition, other factors such as increasing healthcare expenditure and geopolitical uncertainties are expected to trigger the eczema therapeutics market toward witnessing a CAGR of over 9% during the forecast period.

Get more insights into the global trends impacting the future of the eczema therapeutics market.Request Free Sample @https://www.technavio.com/talk-to-us?report=IRTNTR40707

Related Reports on Healthcare Include:

GlobalAllergy Immunotherapies Market- Global allergy immunotherapies market is segmented byproduct (SCIT and SLIT) and geography (Europe, North America, Asia, and ROW).Download Exclusive Free Sample Report

GlobalAllergy Rhinitis Drugs Market- Global allergy rhinitis drugs market is segmented byproduct (antihistamines, intranasal corticosteroids, immunotherapies, and others) and geography (North America, Europe, Asia, and ROW).Download Exclusive Free Sample Report

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Gain instant access to 17,000+ market research reports by usingTechnavio's SUBSCRIPTION platform

About UsTechnavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

ContactTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: [emailprotected]Report: http://www.technavio.com/report/eczema-therapeutics-market-industry-analysis

SOURCE Technavio

Read more from the original source:
$ 4.3 Billion growth expected in Global Eczema Therapeutics Market 2021-2025 | Technavio - PRNewswire

AD is more common in children than in adults, with as many as 1 in 5 children globally affected by the condition compared with about 10% of adults. It can also affect infants, although systemic therapy is rarely utilized in such cases, the authors wrote.

The International Eczema Council recommends that physicians look at nontherapeutic solutions, such as avoiding triggers treating coexistent infections or educating parents and caregivers before considering systemic therapy. However, in cases when systemic therapy is warranted, the investigators said physicians and patients have several choices.

CsA, an immunosuppressive agent, has been shown to be effectivedespite symptoms often returning following cessation of the treatment. The investigators said a systematic review of 15 studies including 602 children and adults found a mean clinical improvement of 55% after 6 to 8 weeks of treatment. However, about half of those patients relapsed within 2 weeks of stopping CsA, and 80% had relapsed by 6 weeks.

It has a rapid onset of action and an acceptable short-term adverse effect profile, they wrote. However, relapse is common upon discontinuation of treatment, and potential long-term side effects are concerning.

The purine analog AZA has also been shown to be effective for both adults and children (who are typically prescribed a half-dose); however, the authors said one of the drugs 3 pathways is degrading to inactive metabolites by thiopurine methyltransferase (TPMT), which means it is not suitable for all patients.

TPMT activity is controlled by a genetic polymorphism, and patients can have high activity, intermediate activity, or low activity, the authors explained.

Patients with intermediate, low, or absent TPMT activity could be at an increased risk of myelotoxicity, the investigators said. In cases with low or absent TPMT activity, the risk could be life-threatening. Thus, the authors said TPMT genotyping or phenotyping is warranted to identify patients at risk of the complication.

MTX, a folic acid antagonist, has not been studied as extensively as the other therapies, but the authors said it has demonstrated similar efficacy to CsA and AZA. Compared with CsA, they said the improvement comes more slowly with MTX; however, MTX led to more durable responses, according to existing data.

Similarly, MMF has not been widely studied. Existing evidence suggests it can be effective in both children and adults with severe AD and may be better tolerated than AZA.

Lastly, the investigators turned to dupilumab, the only biologic approved by the FDA to treat childhood (ages 6 and above) and adult AD. The drug has performed well in clinical trials and has a favorable safety profile, aside from reports of injection-site reactions and conjunctivitis, the investigators said.

Dupilumab is considered the first-line systemic therapy of choice in the management of AD given its effectiveness upon clinical manifestations, excellent benefit/risk profile, and positive impact upon patients and families quality of life, they said.

The investigators said several other biologics and small-molecule drugs are currently being developed and investigated to treat AD, but that therapies appear to provide meaningful relief for many patients.

Ultimately, the choice of systemic therapy depends on each individual patients needs, and patient education is essential to improve treatment adherence, they concluded.

Reference

Davari DR, Nieman EL, McShane DB, Morrell DS. Current perspectives on the systemic management of atopic dermatitis. J Asthma Allergy. 2021;14:595-607. doi:10.2147/JAA.S287638

See the rest here:
Review Finds Several AD Treatment Options, More to Come - AJMC.com Managed Markets Network

AbbVies big expansion for Rinvoq is still unable to move forward, thanks to FDA delays that spell trouble across the entire JAK inhibitor class. But at least one analyst isnt soundingthe alarm yet.

The FDA wont be able to reach decisions for Rinvoqs applications in psoriatic arthritis and ankylosing spondylitis in June as promised, AbbVie said Friday.

The company didnt say whether the agency has provided a new decision date. For the psoriatic arthritis indication, the news marks the second deferral.

The problem arises from the FDAs safety concerns after Pfizers fellow JAK inhibitor Xeljanz turned up additional risks for dangerous heart side effects and cancer in a post-marketing study in patients with rheumatoid arthritis.

RELATED:FDA weighs tighter restrictions for Pfizer's Xeljanz on the heels of safety red flags

In postponing Rinvoq, the FDA said its still reviewing those Pfizer data, according to AbbVie. In February, the agency alerted patients and doctors of Xeljanzs safety signal. At that time, it said it would dig into the results and consider what moves to take.

Existing JAK inhibitors, including Rinvoq, already bear warnings of increased risk of blood clots on their U.S. labels. Xeljanzs cardiovascular red flag obviously made the FDA nervous about it being a class-wide problem for all JAK drugs.

Still, as Piper Sandler analyst Christopher Raymond observedin a Friday note, its unlikely that Rinvoq would be painted with the same brush as Xeljanz, given the AbbVie drug selectively targets JAK1 and has shown a clean cardiovascular and cancer safety profile with rates of about 0.4 and 0.8 events per 100 patient-years, respectively. But Raymond also acknowledged that the new delays and the FDAs stated concern that got passed on from Xeljanz clearly cast more doubt on Rinvoqs label expansion hopes.

RELATED:AbbVie's big Rinvoq ambitions hit an FDA snag as JAK safety questions persist

The changed regulatory timeline does put into question AbbVies target of hitting $8 billion sales for Rinvoq in 2025. But Raymond said hes not hitting the panic button just yet. He also pointed tothe positive opinion from the European Medicines Agencys drug reviewers on approving Rinvoq in atopic dermatitis as a good sign that the drug will eventually pass muster at the FDA.

The FDA has so far delayed multiple decisions for the drug class. Besides psoriatic arthritis and ankylosing spondylitis, it has also pushed back a verdict for Rinvoq in atopic dermatitis to July. AbbVie didnt immediately respond to a request for clarification on the fate of that application.

Other drugs that have suffered similar fate include Xeljanz in ankylosing spondylitis, Eli Lillys Olumiant and Pfizers investigational abrocitinib in atopic dermatitisas well as Incytes Jakafi in chronic graft-versus-host disease and ruxolitinib cream for eczema.

AbbVie has a lot hanging on Rinvoq, which, alongside Skyrizi, is tasked with steadying the ship when megablockbuster immunology drug Humira loses U.S. patent protection in 2023.

Continued here:
AbbVie's big Rinvoq ambitionsand the larger JAK classface even more uncertainty with latest FDA delays - FiercePharma

TUCSON, Ariz. (KGUN) The sun shines over Arizona about 300 days a year, so imagine not being able to sweat or cool down. With temperatures well over 100 degrees in Tucson it leaves most people sweating and finding ways to escape the sun. Thats what Tamela Tibbitts and her family are dealing with every day. Her 8-year-old son Nekoda has ectodermal dysplasia.

We can go outside to the car, and it really wouldnt affect us. He would be red within 2 minutes and then the skin around his mouth would turn yellow. Then he would get sleepy and tired, Tibbitts said.

Tibbitts says if theyre not careful Nekoda can overheat and fast.

Nekoda goes through an entire process before he leaves the house for school or his latest competition. Tamela discovered the National Foundation for Ectodermal Dysplasia when her son was 3 and found out she carries the gene. Other family members are also dealing with the same issue.

"What we do to keep him safe is a lot of water breaks - we have extra cooling equipment. We have large ice packs that we put in his car seat. He has cooling hats. This is his wet vest, which is his favorite, it keeps him cool the longest. The ice vest , we just put the ice packs in, he uses it when it's not too hot and he takes it to school, Tibbitts said.

Tibbitts Family

NFED Executive Director Mary Fete says the condition is rare, and over 180 types of Ectodermal Dysplasias have been discovered so far. The goal of the organization is to educate families and give them the resources they need to stay safe. The disorder affects one in every 10,000 babies.

Symptoms include missing hair, overly thick or thin nails, sweat glands not working properly and missing teeth.

When he was a year old, he didnt have any teeth. By the time he was two no teeth had come in, Tibbitts said. Nekoda wears childhood dentures now.

Fete also says there's a new life-changing clinical trial set for expecting mothers later this year.

This is for moms who are carriers, this is families who know that they are affected. The treatment that will be given before birth into the mom's womb prenatally, and this synthetic protein that they developed, will trigger the signal for the development of normal sweat glands, Fete said.

Tibbitts Family

No matter what youre going through, theres always hope and you can live a full life, Tibbitts said.

For more information on ectodermal dysplasias, visit nfed.org.

See the rest here:
Living without the ability to sweat in Arizona - KGUN

Why Is Your Skin So Good

Do you ever see someone on Instagram and think,Why is your skin so good?We do, so we started asking.

Photo: Courtesy of Carla Oates

Long before people were talking about the microbiome and searching for the perfect bowel movement in the name of beauty, Carla Oates was aware of the link between the gut and skin. I had eczema as a child and a teenager, and at about 13, my mom eliminated certain foods from my diet and introduced other foods, she says. So from a very young age, I saw the connection between what we put into our body and our skin. But it especially hit home when her own daughter experienced eczema at the age of 10 and she stumbled across research that looked at the connection between certain types of bacteria and eczema allergies.

As I explored that link further, I decided to put my family on a gut-healing protocol. That includes taking some of the digestive irritants and foods that cause a lot of problems for people, like dairy, gluten, corn, and soy, completely out of our diet. We became kind of staunch on it and started introducing more probiotic-rich, lacto-fermented foods. I would make coconut kefir and put it in my daughters smoothies. I was making her buckwheat porridge in the morning. I tried to incorporate sauerkraut where I could with the kids, which was a little bit challenging because I didnt always love the taste of it, Oates remembers. And I saw such a huge difference in not only my daughters skin but her focus she had some issues with focusing at school. Oatess own skin healed, too.

Then came the deluge of questions asking what she was doing differently. All I was doing was eating fermented foods, she says. But she received enough inquiries that in 2009, she founded the Beauty Chef, where she creates bio-fermented, probiotic whole-food powders, elixirs, and supplements meant to support gut health, and yes, glowing skin. In the years since, Oates has shared some of her favorite gut-supporting recipes in her books, The Beauty Chef Gut Guide: With 90+ Delicious Recipes and Weekly Meal Plans and The Beauty Chef: Delicious Food for Radiant Skin, Gut Health, and Wellbeing.

Oates recognizes that eating clean and incorporating supplements into your diet can be a luxury, but at its core, she says, its all about going back to the basics. Dont take supplements if you cant afford to get them. Just go back to trying to really embrace a healthy diet. Your microbiome loves fiber, leafy greens, nuts, legumes a Mediterranean diet, basically. Take processed foods out. Incorporate bone broths that are rich in connective tissue. Grow a little garden in your yard, put some spices and herbs in it, and make big batches of stews it can be that simple.

The same goes for your skin-care routine. I have customers saying, Im using this, this, this, this, this, that supplement, and that supplement, and Im not seeing any differences. What can I do? What else can I take? she says. But the people that have the best results, they pare it back. After all, she points out, the skin has its own microbiome. So youve got an ecosystem on your skin, and if youre suffocating it, and confusing your skin with too many ingredients, that causes so many imbalances. Let your skin breathe.

Below, Oates walks us through her go-tos, including the toner that smells like apple-cider vinegar but really works, the face oil that made her skin brighter, and the mineral sunscreen she has been using for years.

GLOW is a bio-fermented whole-foods powder fermentation makes all of the nutrients in the ingredients more bioavailable to the skin. This is not just your daily essential skin powder. Its your daily wellness powder. Its amazing for your gut, but we also get incredible feedback from people saying it improves their skin even hormonal acne. Its great for more lustrous hair, stronger nails, more energy, and a better and happier tummy. Weve had people who notice a difference within a week. We also have people who might have some hormonal acne, and it can take up to a couple of months weve got some incredible before-and-afters.

Weve got lots of different types of bacteria in GLOW thats the base of all of our products and then to make them even more potent and efficacious, we add medicinal herbs. In the powder, we have broad-spectrum B vitamins from sprouted quinoa, biotin, and niacinamide, which is important for skin structural integrity. We have provitamin A from fermented microalgae that is grown in Western Australia, and we know that provitamin A is really important for skin cellular renewal. Its super-rich in polyphenols and antioxidants that are really important for supporting gut health.

I love it with water, and its great in a smoothie it makes every smoothie tastes delicious. Berries and plums have a rosy note, so you do get some of that, but its primarily berry-flavored. Weve got maqui berries in there, and they have higher levels of antioxidants than blueberries, and weve also got grape skins in there. Weve got Kakadu plums, which are Australian plums that have been used for thousands of years in Aboriginal culture for their medicinal benefits.

Ill follow it with our COLLAGEN Inner Beauty Boost, a bio-fermented, probiotic elixir. It doesnt actually contain real collagen but supports your bodys ability to make it and slow down the degradation of existing collagen. Inflammation and oxidative stress are some of the main drivers of the breakdown of collagen, so weve got a host of anti-inflammatory ingredients in it, and its super-rich in antioxidants, too.

I love concocting things. I wrote a book in 2002 called Feeding Your Skin. Its basically a recipe book for skin care Ive made cleansers, moisturizers, and fresh food masks for years. Now oil cleansers are very in vogue.

I use lots of different oils depending on what Ive got in my cupboard, but often, I make a combination of jojoba, apricot, and almond oils I generally dont put more active oils like rosehip in there because youre taking it off anyway. And if I run out of oils, I even just use the olive oil thats in my kitchen.

The type of oil you should use on your skin really depends on your skin type. So, for example, if I had really oily skin, I would not use olive oil to cleanse. But my skin is kind of combination and gets dry in areas, so olive oil will be completely fine for me. I will say that Im such a big believer in people that have really oily skin doing oil cleansing. Lighter oils like jojoba are really effective because when you strip your skin of oil, it sends a message to the brain to produce more oil, which then sends your oil glands into overdrive because theyre like, Oh my God, I need to go into production. So cleansing with oil tricks your brain into thinking youve produced enough oil you just need to make sure that, if youve got really oily skin thats congested and prone to breakouts, you remove it with a warm muslin cloth.

This is a really cool product. I think because were known as an ingestible brand, people forget about it. Occasionally, I will write an email to our team going, Guys, do not forget about the Probiotic Skin Refiner. Its a game-changer!

Basically, its a bio-fermented whole-food extract its the liquid that comes from the fermentation of our powders. Its got a low pH of 3.5, so its naturally exfoliating, and thats because of the lactic-acid fermentation. And you know, lactic acid is also an alpha hydroxy acid (AHA), so it helps to not only increase cellular turnover but also synthesize collagen and increase natural moisturizing patches in the skin.

After I wash my face, I pat it all over with a muslin pad soaked in it. The only thing I would say is that because the Probiotic Skin Refiner is an AHA, make sure that youre putting an SPF on after, especially if youre going outside.

The reason that I never brought it out when we first started the Beauty Chef is hilarious. I had this incredible, nutrient-dense extract that was coming off the fermented foods. I was bottling some of it, and then we were disposing of the rest of it, which was such a waste. But I was using it on my skin, and my friends and family wanted to know what my routine was. I said, Look, Im using this stuff, but it smells really bad. They got really annoyed with me because once they started using it, they were like, I dont understand why you dont put this out in your product range. I said, Because it smells like apple-cider vinegar cause its fermented. Its got a really strong scent. They were like, We dont care: It works. Its amazing. Give us more. One reviewer actually said, My husband goes, Oh my God, what is that smell? I was lying in bed next to him. But genuinely, if you put a cream on top of it, the smell dissipates within seconds, and because its so effective, people just dont seem to care.

I do moisturize a bit more as Im aging. Im predisposed to eczema. Since I began paying attention to my gut, I havent had a really bad eczema breakout for like 20-something years, which is amazing, but I do genetically have dry skin. My son and I were talking about it the other night. Like, my mom had really scaly legs, and now both of my kids are prone to eczema as well because my husband has eczema, so they got a double whammy of being predisposed to really dry skin.

Emma Lewishams a New Zealander, and I have just been introduced to her. Shes focused on sustainability and generous with sharing information about her journey and how she is moving toward truly sustainable packaging. And not only that, but her products are highly efficacious. Theyre rich in natural botanicals. This is called the 72-Hour Crme, and Ive really noticed that my skin looks so much plumper. It really does give my skin that kind of dewy radiance that I love I dont mind that feeling when I put on some oil and then I put on a really beautiful moisturizer that makes my skin kind of shiny and dewy; I much prefer that to feeling like my skin is cracking. Its got a lovely smell; its very subtle, a little bit soapy. Its sort of old-fashioned but vegan and cruelty-free.

Photo: Courtesy of the Retailer

I love Marie Veroniques story her daughters a scientist, and they did the range together. Her products have lots of really amazing natural ingredients, but theyre also highly active. In this oil, specifically, I love the combination of high-performing actives with carotenoid antioxidants, which are amazing for protecting the skin from free-radical damage and helping to prevent collagen from degradation. Its also rich in essential fatty acids, which are crucial for maintaining and building a healthy skin barrier. Ill alternate it with Sunday Rileys C.E.O. Glow Vitamin C + Turmeric Face Oil (below).

I love vitamin C, and I love turmeric theyre both anti-inflammatory. I definitely noticed a difference in my skin tone and texture with this. Theyre brighter and smoother. Its a really beautiful oil.

I used to put coconut oil it was called Reef Oil on as a teenager and bake my skin. And I saw a facialist, I think was in my early 20s, and she said, Carla, youve got some sun damage. So I became much more conscious about sun protection, but I grew up in Australia in the 70s. And, oh my gosh, my mom was always out in the sun with her Reef Oil on as well. I will say that vitamin D is also really good for your skin, your immune health, and your bone health, and that a percentage of the worlds population is deficient in vitamin D, but lets find that balance between getting enough and protecting ourselves.

Ive been using mineral sunscreens for a long time I prefer ingredients like zinc oxide that physically protect you from the sun. But the problem with a lot of physical blockers is that they make your skin look white. Sometimes my husband at the beach will be like, Oh my God. Especially when youre going out to work, you dont want to look like youve got this white face. So what I love about this Coola sunscreen is that its really smooth and it dissipates. You dont notice it, and its such a great experience. Its also fragrance free.

Get the Cut newsletter delivered daily

See the rest here:
How This Gut-Health Advocate Gets Her Skin So Good - The Cut

Hand sanitizer has become more popular than ever, in large part due to its effectiveness during the COVID-19 pandemic. Portable hand sanitizer products kill germs on your hands and other surfaces on contact, helping to slow the spread of transmissible diseases like COVID-19.

Hand sanitizer has proven itself useful in killing germs, but using it can have side effects. Overuse of hand sanitizer can lead to dry, cracked skin as well as redness or discoloration, and flaking. It can also pose a risk if its ingested or gets into your eyes.

Lets cover everything you need to know about using hand sanitizer safely.

The side effects of your hand sanitizer will come down to the formulas youre using. Hand sanitizer typically contains a high amount of alcohol (between 60 and 95 percent) meant to kill germs on your hands. Even if the alcohol content is low, your hand sanitizer may also contain other antiseptic ingredients that have been known to cause side effects.

Alcohol is an effective antiseptic, meaning that its proven to kill bacteria and viruses on organic surfaces. But alcohol is also known to have a drying effect on your skin.

When youre applying hand sanitizer to your hands multiple times each day, the product is taking moisture out of your skin. This can result in skin thats dry, flaky, and sensitive to the touch. In addition to being uncomfortable, the American Academy of Dermatology Association says that having dry skin can actually increase your chances of picking up germs.

You may notice that after hand sanitizer dries on your hands, itchy and red or discolored eczema patches tend to appear. Thats because if you have eczema, the chemicals can actually make your symptoms worse. Whether you use a foam, liquid, or a gel-based hand sanitizer, you may see increased eczema symptoms after use.

Hand sanitizer sometimes contains an ingredient called triclosan. According to the FDA, Triclosan is intended to kill bacteria, and has been used in products from toothpaste to body wash. The FDA also says some studies have indicated that high exposure to triclosan may disrupt natural hormone cycles and even impact fertility. More research is needed to fully understand triclosans impact on people, but the ingredient has already been banned from several types of products.

The FDA says that triclosan is intended to kill bacteria, but overuse of this ingredient in consumer products may be contributing to the rise in antibiotic-resistant bacteria. A 2015 research review of how triclosan is contributing to antibiotic resistance concluded that more research is necessary to determine how this chemical is actually impacting human health.

There are risks for using hand sanitizer, especially if you use it in ways other than instructed on the package instructions. These risks can typically be avoided by sticking to external use of hand sanitizer and avoiding contact with your eyes.

The high amounts of alcohol and other ingredients make hand sanitizer unsafe for human consumption. Texas Medical Center says that anyone who swallows a significant quantity of hand sanitizer can get sick with symptoms that resemble alcohol poisoning.

Hand sanitizer is meant for external use only. If you or someone you know has ingested it, call the Poison Control Hotline at 800-222-1222.

Its easy enough to apply hand sanitizer and accidentally touch your eye shortly afterward. But the high levels of alcohol in hand sanitizer can actually cause chemical burns on the outer layer of your eye. Typically, damage caused by hand sanitizer to your eyes will completely heal, but you may experience the following symptoms while it heals:

Theres a reason that doctors recommend washing your hands with soap and water over using hand sanitizer. Its because its very simple to accidentally overdo it with hand sanitizer and cause dry skin and other side effects.

In fact, if you use hand sanitizer so much that your hands get dried out, it may be easier for your hands to pick up germs from other surfaces.

Additionally, your skin may start to crack or bleed. Skin thats dried out and cracked may also be more susceptible to bacteria.

Read ingredient labels before you buy hand sanitizer and limit how much you use it to the product labels recommendations. For best results:

When used properly, hand sanitizer does have benefits, including:

To use hand sanitizer correctly, you should only use it when your hands are free from visible dirt. Use only a dime-sized amount (or less) and rub your hands together until the hand sanitizer has completely absorbed. For best results (and healthy skin), apply a moisturizer as soon as possible after the hand sanitizer has dried. This will help prevent some of the less than desirable side effects.

When hand sanitizer is used correctly, side effects and risks are minimal. When you overuse the product, it can cause dry hands and cracked skin. Some ingredients in hand sanitizer, such as triclosan, may cause health complications if you are exposed to them in large amounts. Always read ingredient labels before you buy and only use hand sanitizer according to the guidance on the product label.

See original here:
Side Effects of Hand Sanitizer, Risks, and How to Use It Safely - Healthline

Sanofi S.A. Regeneron Pharmaceuticals Inc.

LEO Pharma A/S

Medimmune LLC. (AstraZeneca)

Impact Analysis of COVID-19 Pandemic on Businesses: Know Short Term and Long Term Impact

Most of the businesses are facing a growing litany of business-critical concerns related to the coronavirus outbreak, including supply chain disruptions, a risk of a recession, and a potential drop in consumer spending. All these scenarios will play out differently across various regions and industries, making accurate and timely market research more essential than ever.

We at Facts and Factors (www.fnfresearch.com) understand how difficult it is for you to plan, strategize, or make business decisions, and as such, we have your back to support you in these uncertain times with our research insights. Our team of consultants, analysts, and experts has developed an analytical model tool for markets that helps us to assess the impact of the virus more effectively on the industrial markets. We are further implementing these insights into our reports for a better understanding of our clients.

Industry study presents the global Atopic Eczema Treatment market size, historical breakdown data (2014-2019), and forecast (2020-2026). Production, revenue, and market share by key vendors, key regions, and type; The consumption of Atopic Eczema Treatment market in terms of volume is also provided for major countries (or regions), and for each application and product at the global level.

Inquire more before buying this report Here: https://www.fnfresearch.com/inquiry/atopic-eczema-treatment-market

Key Answers in the Report

In this study, the years considered to estimate the market size of Atopic Eczema Treatment Market:

Geographically, this report is segmented into several key regions, with sales, revenue, market share, and growth rate of Atopic Eczema Treatment in these regions, from 2020 to 2026, covering

Reasons to Buy the Report

Browse detailed report with in-depth TOC @ https://www.fnfresearch.com/atopic-eczema-treatment-market

Segmentation

As discussed earlier, there is segmentation in the Atopic Eczema Treatment Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Atopic Eczema Treatment Market. At the same time, there is an emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Atopic Eczema Treatment Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Atopic Eczema Treatment Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows the Middle East and Africa, South and North America, Europe, and the Asia Pacific. From the Atopic Eczema Treatment Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Atopic Eczema Treatment Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Atopic Eczema Treatment Market report.

About Us:

Facts & Factors is a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing a planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background.

Contact Us:

Facts & Factors

USA: +1-347-989-3985

Email: sales@fnfresearch.com

Web: https://www.fnfresearch.com

Read the original post:
Atopic Eczema Treatment Market 2020 : Research Reveals Enhanced Growth During The Forecast Period 2026 KSU | The Sentinel Newspaper - KSU | The...

Incyte had a particularly big week scheduled with the U.S. Food and Drug Administration (FDA), which included two PDUFA dates and an advisory committee meeting. In addition, Ascendis had a target action date. However, the agency had a chance of plans. Read on for more information.

Incytes Ruxolitinib Cream for Atopic Dermatitis

Incytehas a target action date of June 21, 2021, for its New Drug Application (NDA) for ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application for atopic dermatitis (AD), a type of eczema. The NDA included data from the Phase III TRuE-AD clinical trial program of more than 1,200 people ages 12 and older. The company submitted a priority review voucher (PRV) with the NDA. The use of the PRV shortens the review period by four weeks. On June 11, the company reported the FDA had extended the review period for the NDA by three months to September 21, 2021. The agency indicated it needed time to review additional analyses the company submitted in response to an information request.

At the companys first-quarter financial report on May 4, Herve Hoppenot, Incytes chief executive officer, said, We expect an exciting year ahead for Incyte with the potential for multiple approvals, including ruxolitinib cream in atopic dermatitis, and several regulatory filings, notably parsaclisib in NHL and ruxolitinib cream in vitiligo. We are also initiating pivotal trials across key development programs for both tafasitamab and LIMBER this year.

Incytes Ruxolitinib for Steroid-Refractory Chronic Graft-Versus-Host Disease

Incyte also has a target action date of June 22 for its supplemental NDA for ruxoliltinib (Jakafi) for treatment of steroid-refractory chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. This sNDA is built on data from the Phase III REACH3 trial comparing ruxolitinib with best available therapy (BAT) in this patient population. In that study, patients receiving ruxolitinib had a significantly greater overall response rate (ORR) compared to BAT at Week 24, which was the primary endpoint of the study. The ORR was 49.7% in the ruxolitinib group compared to 25.6% in the BAT cohort. On June 8, 2021, Incyte announced the FDA had also extended the review period for the sNDA for Jakafi for this indication until September 22, 2021. Again, it was in response to additional information submitted as part of an FDA information request.

Chronic GVHD is a life-threatening complication following stem cell transplant that burdens a vulnerable patient population, which today has limited treatment options, said Peter Langmuir, Group Vice President, Oncology Targeted Therapies, Incyte, in a February 2021 statement. The acceptance of this sNDA represents an important milestone for Incyte as we continue our work towards helping more people living with GVHD, particularly for those who do not respond to steroids. We look forward to working closely with the FDA to bring this innovative therapy to patients and to providing continued support to the GVHD community in the United States.

FDAs AdCom to Review Incytes BLA for Retifanlimab Injection for Anal Cancer

In what is clearly a busy week for Incyte, the FDAs Oncologic Drugs Advisory Committee is holding a meeting on June 24 to discuss the companys Biologics License Application (BLA) for retifanlimab injection for the treatment of adults with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy.

The BLA was accepted for Priority Review on January 21, 2021, and has a target action date of July 25, 2021. The submission was based on data from the Phase II POD1UM-202 trial. It enrolled 94 patients, including several with well-controlled HIV infection. There was an ORR of 14% for retifanlimab monotherapy.

Patients with SCAC who have progressed after first-line chemotherapy treatment currently have no approved treatments available, and we are encouraged that the FDAs acceptance of this BLA for Priority Review brings us one step closer to addressing this historically neglected, yet important, tumor, said Lance Leopold, Group Vice President, Immuno-Oncology Clinical Development, Incyte, in a January 21 statement. Despite SCAC being a rare disease, its incidence is increasing, and its impact is profound. We look forward to working with the FDA to potentially fill an unmet need and advance progress in SCAC for patients.

Ascendiss TransCon hGH for Pediatric GHD

Ascendis Pharmahas a target action date of June 25 for its BLA of TransCon hGH (lonapegsomatropin) for the treatment of pediatric Growth Hormone Deficiency (GHD). The drug is designed to release somatropin with the same action and distribution as once-a-day somatropin products, but with a once-a-week injection. The BLA is based on a clinical development program including eight clinical trials in more than 400 patients with GHD. In pediatric GHD, the pituitary gland does not generate enough growth hormone. The children are short, but may also experience metabolic abnormalities, psychosocial challenges and poor quality of life. The standard of care for GHD is a daily subcutaneous injection of hGH. On June 11, the FDA pushed back the PDUFA date until September 25, 2021. Ascendis indicated, like with the previous Incyte announcements, that after an FDA information request, the agency decided it was a major amendment and extended the target action date in order to provide more time to review the data.

During the companys first-quarter financial report on May 27, Jan Mikkelson, Ascendis Pharmas president and chief executive officer stated, With potential U.S. FDA approval for TransCon hGH now less than a month away, we believe we are one step closer to fulfilling our Vision 3x3 to build a leading biopharma company. Guided by our values of patients, science and passion, we have built a pipeline of three differentiated endocrinology rare disease product candidates by applying our TransCon technology to clinically validated parent drugs and/or targets. Each candidate targeting substantial unmet medical needs in larger markets where we have the potential to become the market leader.

At the new deadline, Mikkelsen stated, We have responded to all outstanding questions from the FDA and believe the complete package we have submitted satisfies all of FDAs requests and will enable a complete review of the application of lonapegsomatropin for pediatric GHD. We are committed to making lonapegsomatropin the market-leading therapy for treating pediatric GHD and look forward to continuing interactions with the FDA during the remainder of the review process.

See the article here:
FDA Action Alert: Incyte and Ascendis - BioSpace

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Commission (EC) has approved Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The European approval makes Adtralza the first high affinity, fully human monoclonal antibody approved to specifically bind to and inhibit the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.1,4,5

Adtralza will be available in a 150 mg/mL prefilled syringe for subcutaneous injection with an initial dose of 600 mg followed by 300 mg every other week.1 Adtralza can be used with or without topical corticosteroids (TCS).1

This European Commission approval of Adtralza means that clinicians across Europe now have an important new treatment option for adult patients with moderate-to-severe atopic dermatitis, which is a chronic, unpredictable skin disease, said Stephan Weidinger, MD, Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany and tralokinumab clinical trial investigator. By specifically targeting IL-13 with high affinity, Adtralza has demonstrated that it can reduce atopic dermatitis signs and symptoms and sustain improvements over time.

The approval is based primarily on efficacy and safety results from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase 3 trials, which included more than 1,900 adult patients with moderate-to-severe atopic dermatitis.1 Safety data was evaluated from a pool of five randomized, double-blind, placebo-controlled trials, including ECZTRA 1, 2 and ECZTRA 3, a dose-ranging trial, and a vaccine response trial.1

This European Commission approval of Adtralza is an important development for the millions of adults in Europe who are living with this often uncontrolled skin disease, said Catherine Mazzacco, President and CEO of LEO Pharma. We are proud to have the opportunity to offer a new long-term treatment option for moderate-to-severe atopic dermatitis and are working closely with key stakeholders to enable access to Adtralza for eligible patients.

The European Commission decision is valid in all European Union Member States, Iceland, Norway, and Liechtenstein. Additional regulatory filings are underway with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom and other health authorities worldwide.

About Adtralza (tralokinumab)

Adtralza (tralokinumab) is a fully human, monoclonal antibody developed to specifically neutralize the IL-13 cytokine, which plays a key role in the immune process underlying atopic dermatitis signs and symptoms. Adtralza specifically binds to the IL-13 cytokine with high affinity, thereby preventing interaction with the IL-13 receptor 1 and 2 subunits (IL-13R1 and IL-13R2).4,5

About the pivotal ECZTRA 1, 2, and ECZTRA 3 Trials

ECZTRA 1 and ECZTRA 2 (ECZema TRAlokinumab trials Nos. 1 and 2) were randomized, double-blind, placebo-controlled, multinational 52-week trials, which included 802 and 794 adult patients, respectively, to evaluate the safety and efficacy of Adtralza (300 mg) as monotherapy in adults with moderate-to-severe atopic dermatitis who were candidates for systemic therapy.2

ECZTRA 3 (ECZema TRAlokinumab trial No. 3) was a double-blind, randomized, placebo-controlled, multinational 32-week trial, which included 380 adult patients, to evaluate the safety and efficacy of Adtralza (300 mg) in combination with TCS in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.3

About atopic dermatitis

Atopic dermatitis is a chronic, inflammatory, skin disease characterized by intense itch and eczematous lesions.6 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.7 Type 2 cytokines, including IL-13, play a central role in the key aspects of atopic dermatitis pathophysiology.4

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million. For more information please visit http://www.LEO-Pharma.com.

References

June 2021 MAT-46806

More here:
LEO Pharma announces European Commission approval of Adtralza (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults...

Atopic Eczema Treatment Market

Facts & Factors (FnF) published a market research report onAtopic Eczema Treatment Market By Type (Topical, Oral, and Injectable), By Application (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 2026includes 190+ pages of research PDF with TOC including a list of table and figures in its research offerings.

FnF Research presents an updated and Latest Study onAtopic Eczema Treatment Market2020-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Atopic Eczema Treatment market during the forecast period (2020-2029).

According to the research report, " [195+ Pages Report] Global atopic eczema treatment market size & share estimated to reach USD 34,089.3 Million by 2026, growing at a CAGR of 10.36% between 2020 and 2026. Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. "

The historical and forecast information provided in the report span between 2018 and 2026. The report provides detailed volume analysis and region-wise market size analysis of the market.

Request Updated Free Sample Research Report on Atopic Eczema Treatment Market:https://www.fnfresearch.com/sample/atopic-eczema-treatment-market

(The free sample of this report is readily available on request and updated with new research additions).

What benefits does FNF research study is going to provide?

Atopic Eczema Treatment Market by Top Manufacturers (2020-2026)

Impact Analysis of COVID-19 Pandemic on Businesses: Know Short Term and Long Term Impact

Most of the businesses are facing a growing litany of business-critical concerns related to the coronavirus outbreak, including supply chain disruptions, a risk of a recession, and a potential drop in consumer spending. All these scenarios will play out differently across various regions and industries, making accurate and timely market research more essential than ever.

We at Facts and Factors (www.fnfresearch.com) understand how difficult it is for you to plan, strategize, or make business decisions, and as such, we have your back to support you in these uncertain times with our research insights. Our team of consultants, analysts, and experts has developed an analytical model tool for markets that helps us to assess the impact of the virus more effectively on the industrial markets. We are further implementing these insights into our reports for a better understanding of our clients.

Industry study presents the global Atopic Eczema Treatment market size, historical breakdown data (2014-2019), and forecast (2020-2026). Production, revenue, and market share by key vendors, key regions, and type; The consumption of Atopic Eczema Treatment market in terms of volume is also provided for major countries (or regions), and for each application and product at the global level.

Inquire more before buying this report Here:https://www.fnfresearch.com/inquiry/atopic-eczema-treatment-market

Key Answers in the Report

In this study, the years considered to estimate the market size of Atopic Eczema Treatment Market:

Geographically,this report is segmented into severalkey regions, with sales, revenue, market share, and growth rate of Atopic Eczema Treatment in these regions, from 2020 to 2026, covering

Reasons to Buy the Report

Browse detailed report with in-depth TOC @https://www.fnfresearch.com/atopic-eczema-treatment-market

Segmentation

As discussed earlier, there is segmentation in theAtopic Eczema Treatment Marketreport, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Atopic Eczema Treatment Market. At the same time, there is an emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Atopic Eczema Treatment Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of theAtopic Eczema Treatment Marketreport, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows the Middle East and Africa, South and North America, Europe, and the Asia Pacific. From the Atopic Eczema Treatment Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From thisAtopic Eczema Treatment Marketreport, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Atopic Eczema Treatment Market report.

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing a planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background.

Contact Us:

Facts & Factors

USA: +1-347-989-3985

Email:sales@fnfresearch.com

Web:https://www.fnfresearch.com

View original post here:
Atopic Eczema Treatment Market Projected to Reach USD 34089.3 Million by 2026 - Biophotonics.World